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Background: Polybutylcyanoacrylate (PBCA) nanoparticles coated with polysorbate-80 have 
been extensively proposed for delivering drugs into the animal brain and have shown great 
potential for therapeutic applications. In this study, we made an attempt to deliver the chemo-
therapeutic drug, temozolomide, into the brain by using PBCA nanoparticles. The physicochemi-
cal characteristics, in vitro release, and brain targeting ability of the drug-loaded nanoparticles 
were investigated.
Results: Our results show that a significantly higher concentration of temozolomide in the form 
of polysorbate-80-coated PBCA nanoparticles was observed in the brain (P , 0.05) in com-
parison with the free drug.
Conclusion: This study indicates that polysorbate-80 coated PBCA nanoparticles could be a 
feasible carrier for temozolomide delivery to the brain. It is anticipated that the developed 
formulation may improve on targeted therapy for malignant brain tumors in the future.
Keywords: temozolomide, polybutylcyanoacrylate, nanoparticles, polysorbate-80, brain 
targeting
Introduction
The treatment of malignant brain tumors is one of the most challenging issues in central 
nervous system diseases, especially glioblastoma, for which the median survival time 
of patients is still less than 1 year at present.1 The failure of chemotherapy in these 
tumors is attributed not to the chemotherapeutic activity of the available drugs, but to 
the existence of an insurmountable obstacle, ie, the blood–brain barrier. The blood–
brain barrier, formed by the endothelial cells of the brain capillaries coupled together 
by tight junctions (zonulae occludentes), inhibits the transport of 98% of all small-
molecule drugs and 100% of large-molecule pharmaceutics into the brain.2,3 Therefore, 
it is difficult to deliver effective drug concentrations to the tumor site in the brain.
In the past few years, a number of different approaches have been developed for 
drugs to overcome this barrier. The methods include direct injection into the brain,4 
osmotic opening of the tight junctions,5 drug structural modifications,6 chemical drug 
delivery systems, and nanoparticulate carriers, such as liposomes,7,8 solid lipid nano-
particles, or polymeric nanoparticles.9,10 Among these various noninvasive strategies, 
polymeric nanoparticles seem to be one of the most promising and exciting techniques 
for central nervous system drug delivery. Polymers are made of natural or synthetic 
materials, with sizes ranging from 1 to 1000 nm, into which the drug load is encap-
sulated, passively adsorbed, or chemically linked to the surface.10,11 On the one hand, 
nanoparticles can protect the entrapped drugs from degradation so as to increase the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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drug concentration at the targeted site, and on the other hand, 
by modifying the property of the nanoparticle surfaces with 
surfactants, nanoparticles can improve drug delivery by avoid-
ing uptake by the reticuloendothelial system in the body.12 
Therefore, nanoparticles are increasingly demonstrating 
their advantage of effective transporting of various different 
drugs across the blood–brain barrier on the basis of their 
small size and appropriate surface functionalization.11
Polybutylcyanoacrylate (PBCA), a minimally toxic, 
biocompatible, and biodegradable polymer, has been exten-
sively investigated as a drug carrier in recent years. It is easy 
to synthesize and scale up, and possesses the abilities of 
altering the biodistribution of loaded drugs and modulating 
drug release characteristics.13,14 Most importantly, many 
studies have showed that PBCA nanoparticles are able to 
transport therapeutic agents in significant quantities across 
the blood–brain barrier into the brain when coated with 
surfactant polysorbate-80 on their surfaces. These drugs 
include anticancer agents,13,15 analgesics,16 peptides,17 N-methyl- 
D-aspartate receptor antagonists,18 antibiotics, and non-
steroidal anti-inflammatory drugs.19,20 The precise mechanism 
of delivery of drug-loaded polysorbate-80 coated PBCA 
nanoparticles is still not fully clarified. It appears to be 
achieved by covalent coupling with apolipoprotein E, A-I, 
or B-100, followed by receptor-mediated endocytosis of the 
nanoparticles by the brain capillary endothelial cells.21,22
Temozolomide (3,4-dihydro-3-methyl-4-oxoimidazo 
[5,1-d]-as-tetrazine-8-carboxamide [TMZ]; see Figure 1), 
first synthesized by the UK Cancer Research Campaign in 
the 1980s, is a cytotoxic alkylating agent with a chemical 
formula of C6H6N6O2 and a molecular weight of 194.15.23 
The solubility of TMZ in normal saline is 3.1 mg/mL.24 It has 
been shown to be one of the most effective antineoplastic 
agents for treating high-grade glioma and metastatic melanoma. 
Unfortunately, due to its short half-life of approximately 
1.8 hours in plasma, TMZ has to be administered with high 
systemic doses to reach therapeutic brain levels, which 
simultaneously brings about a series of side effects, including 
bone marrow depression, oral ulcerations, nausea, vomiting, 
fatigue, and headache.25 In order to get better efficacy for 
treating brain tumors and reduce related toxicity and side effects 
during chemotherapy, it is necessary to identify the most effi-
cient way to achieve drug targeting for meeting the require-
ments of modern therapy, and perhaps polymeric nanoparticles 
as a drug delivery system is a good choice. Hence, in the 
present research work, the possibility of targeting delivery 
of TMZ with polysorbate-80 coated PBCA nanoparticles 
into the brain was investigated.
Material and methods
Materials
TMZ powder was a gift from Jiangsu Tasly Diyi Pharmaceuti-
cal Co Ltd (Huaian, China). The monomer n-butylcyanoacrylate 
(n-BCA) was purchased from Guangzhou Baiyun Medical 
Adhesive Co Ltd (Guangzhou, China). Polysorbate-80 was 
obtained from Sigma Chemical Co (St. Louis, MO). Pluronic 
F68 and D-mannitol were purchased from Bio Basic Inc 
(Markham, Canada). All other materials and reagents used 
were of analytical/high-pressure liquid chromatography 
grade and without further purification. The glassware were 
thoroughly cleaned and rinsed with deionized water.
Preparation of nanoparticles
The preparation of PBCA nanoparticles containing TMZ 
was performed according to the method of emulsion 
polymerization,17 with minor modifications. Briefly, under 
constant magnetic stirring, 1% n-BCA monomer was added 
dropwise to 10 mL of solution (pH 2.5 adjusted with 0.1 N HCl) 
containing 1% Pluronic F68 and 5 mg TMZ. After stirring 
at 500 rpm for 4 hours at room temperature, the pH value 
of the nanoparticle suspension was adjusted to 5.0 ± 0.5 with 
0.1 N sodium hydroxide solution, and then the stirring was 
continued for another 30 minutes to complete the reaction. 
The resulting suspension was filtered through a sintered 
glass filter (pore size 10 µm) to remove any agglomerates. 
Subsequently, the colloidal suspension was frozen by dry ice 
and freeze-dried (FDU-1200; EYELA, Tokyo, Japan) after 
addition of 3% mannitol as a cryoprotector. The lyophilized 
powder was resuspended in saline containing 1% anhydrous 
glucose. For surfactant coating, 1% polysorbate-80 was 
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added and the mixture was incubated for 30 minutes 
at   ambient temperature under constant stirring prior to 
  administration. The drug-free nanoparticles were prepared 
using the same technique.16
Preparation of solution of free TMZ
TMZ solution was prepared by dissolving 5 mg of TMZ with 
dimethyl sulfoxide in 0.9% saline (20%, v/v) for intravenous 
administration and administered within four hours.26
Analysis of particle size and surface 
charge
The particle sizes and surface charges (zeta potentials) of the 
nanoparticles were measured on a Nano-ZS Zetasizer 
dynamic light scattering detector (Malvern Instruments, 
Malvern, UK) equipped with a 4.0 mW internal laser. 
All measurements were performed at 25°C at a scattering 
angle of 173°. Prior to measurement, the suspensions were 
diluted with deionized water to an appropriate concentration 
for better measurement. Values of the particle sizes and zeta 
potentials are presented as mean ± standard deviation (SD) 
from three replicate samples. The width of the size distribu-
tions were characterized by the polydispersity index.
Particulate morphology
Nanoparticle suspension was dropped onto a copper grid and 
dyed with 2% phosphotungstic acid, and the morphology of 
the nanoparticles was then observed by negative staining 
under a transmission electron microscope (JEM-2100HC; 
JEOL, Tokyo, Japan).
Fourier transform infrared spectroscopy
The Fourier transform infrared spectra were recorded using 
a AVATAR360 FTIR spectrometer (Nicolet, Madison, WI) 
at a resolution of 4 cm−1, and 256 scans were taken in the 
range 400–4000 cm−1. The sample of the nanoparticles (with 
and without drug) or TMZ used for the Fourier transform 
infrared spectroscopic characterization were prepared by 
grinding the dry specimens with spectroscopic grade KBr 
and pressing them to form disks.
Determination of drug loading and 
entrapment efficiency
Before freeze-drying, the nanoparticle suspension was cen-
trifuged (Avanti J-E; Beckman Coulter, Brea, CA) at 20,000 
rpm for 30 minutes at 4°C. The concentrations of TMZ in 
the supernatant were diluted with 0.1 N HCl and then 
  measured at a wavelength of 329 nm using an ultraviolet 
spectrophotometer (Beckman Coulter). The entrapment 
efficiency was calculated as the difference between the 
amount of drug entrapped in the nanoparticles and the 
total amount of drug, while drug loading was determined as 
drug analyzed in the nanoparticles versus the weight of the 
final polymer mass after drying.
evaluation of in vitro release
The in vitro release was studied using a dialysis bag diffu-
sion technique.27,28 The TMZ-loaded nanoparticle suspension 
(coated and uncoated with polysorbate-80) or TMZ solution 
was placed in cellulose dialysis bags (cutoff 3.5 kDa; Solarbio), 
which were sealed at both ends, and then the bags were 
dipped into the crystallizing dishes containing 200 mL 
phosphate-buffered saline (pH 6.8), which were maintained 
at 37°C and constantly stirred at 100 rpm. The crystallizing 
dishes were closed to prevent evaporation of the release 
medium. At regular time intervals, 2 mL of dissolution medium 
was withdrawn and the same volume of fresh phosphate-
buffered saline was added accordingly. The amount of TMZ 
in the medium was measured by high-pressure liquid chro-
matography analysis.
Animal testing
Healthy adult Wistar rats weighing 180–220 g were pur-
chased from the Medical School Laboratory Animal Center 
at Xiamen University and used for body distribution studies. 
They had access to food and water ad libitum. All animals 
were provided with humane care according to the Principles 
of Laboratory Animal Care formulated by the National 
Society for Medical Research and the Guide for the Care and 
Use of Laboratory Animals prepared by the Institute of 
Laboratory Animal Resources and published by the National 
Institutes of Health (Publication 86–32, revised 1985). The rats 
were randomly divided into four groups with six animals 
per group. Group 1 was injected with TMZ solution into the 
tail vein, Group 2 was treated with TMZ-PBCA nanoparticles, 
Group 3 was given 1% polysorbate-80 coated TMZ-PBCA 
nanoparticles, and Group 4 served as the control. All formu-
lations were administered at a dose of 10 mg of TMZ/kg.27 
One hour after injection, the rats were anesthesitized with 
ethyl ether and sacrificed by decapitation.29,30 The selected 
organs, ie, the brain, lungs, heart, liver, spleen, and kidneys, 
were quickly dissected and stored at −20°C. The amount of 
drug in each organ was measured by high-pressure liquid 
chromatography analysis.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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high-pressure liquid chromatography 
analysis of TMZ
TMZ content was measured by high-pressure liquid 
  chromatography/ultraviolet absorption (Waters 2695 and 2996; 
Waters, Milford, MA) at a wavelength of 329 nm, and a 
Hypersil C18 ODS column (5 µm, 250 mm × 4.6 mm; Elite, 
Dalian, China) was used. The mobile phase methanol/0.5% 
glacial acetic acid solution (10:90, v/v) was delivered at a 
flow rate of 1 mL/min at ambient temperature.27 All organ 
samples were homogenized, and each homogenate sample 
was then mixed with acetone and vortexed for two minutes. 
After centrifugation at 4000 rpm for 15 minutes at 4°C, the 
supernatant was evaporated to dryness under nitrogen stream 
at 60°C. Finally, the residue was dissolved in 200 µL mobile 
phase and 20 µL of the solution was injected into the high-
pressure liquid chromatography system for analysis.
statistical analysis
The results were presented as mean ± SD calculated over at 
least three data points. Statistical significance of differences 
was processed by one-way analysis of variance and a subse-
quent post hoc Tukey comparison. A value of P , 0.05 was 
considered to be statistically significant.
Results
Physicochemical characteristics  
of nanoparticles
Figure 2 shows the transmission electron microscopy mor-
phology of TMZ-PBCA nanoparticles with an average 
diameter of about 120 nm. Most nanoparticles could be 
observed to be of spherical or ellipsoidal shape with a rela-
tively smooth surface. Coinciding with transmission electron 
microscopic photography, dynamic light scattering results 
indicated that the average size of the TMZ-PBCA nanopar-
ticles was 135.8 ± 11.3 nm (n = 9), and polydispersity indices 
ranged from 0.191 to 0.306. The surface of nanoparticles 
carried negative charges, with a mean zeta potential 
of −24.8 ± 2.2 mV (n = 9) in deionized water. The entrapment 
efficiency was 44.23 ± 2.04% (n = 3), and drug loading was 
2.80 ± 0.05% (n = 3).
Figure 3 shows the Fourier transform infrared spectra of 
TMZ, PBCA nanoparticles, and TMZ-PBCA nanoparticles 
obtained in the present study and it was performed to 
verify drug entrapped into the nanoparticles. As revealed in 
  spectrum, the main four functional groups of PBCA nano-
particles were C−H, 2950 cm−1, C≡N, 2250 cm−1, C=O, 
1750 cm−1, and C−O, 1250 cm−1. In the Fourier transform 
infrared spectra of TMZ, two strong characteristic bands 
were observed at 3400 cm−1 and 1610 cm−1. The first was due 
to the N-H stretching mode and the second corresponded to 
the C=C or C=N stretching vibration, while in the spectrum 
of TMZ-PBCA nanoparticles, the presence of the character-
istic bands of TMZ and PBCA nanoparticles was found at 
the same place simultaneously.
evaluation of in vitro release
The release profiles of TMZ solution, TMZ-PBCA, and 
TMZ-PBCA nanoparticles coated with polysorbate-80 are 
shown in Figure 4. As shown in the releasing curve, we 
observed that approximately 80% of TMZ had been released 
from TMZ solution after one hour, but the cumulative release 
of the drug from nanoparticles was slow. By 24 hours, the 
total cumulative releases from the TMZ-PBCA nanoparticles 
and TMZ-PBCA nanoparticles coated with polysorbate-80 
were 66.03 ± 1.61% and 62.97 ± 1.40%, respectively. 
A
200 nm
100 nm
B
Figure 2 TeM image of TMZ-PBcA-NPs prepared by emulsion polymerization. 
Bars represent 200 nm A) and 100 nm B).
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Table 1 shows the different fitting model results of the nano-
particles without coating and coated with polysorbate-80. 
Both were fitted to Higuchi and Ritger–Peppas equations 
better with higher r2 values.
Animal testing
Table 2 and Figure 5 show the TMZ concentrations (µg/g) in 
different organs after intravenous administration in rats. When 
the rats were given TMZ solution, the concentrations of TMZ 
in the heart, liver, spleen, lungs, and kidneys after one hour 
were 3.29 ± 0.23, 3.26 ± 0.35, 2.11 ± 0.17, 1.95 ± 0.12, and 
5.17 ± 0.47 µg/g, respectively. However, lower concentrations 
were observed in the heart and kidneys (2.19 ± 0.29, 
1.68 ± 0.26 µg/g and 4.09 ± 0.37, 3.71 ± 0.30 µg/g) after treating 
the rats with TMZ-PBCA nanoparticles and nanoparticles 
coated with polysorbate-80, which is in accordance with data 
already reported.13 Higher concentrations observed in the liver, 
spleen, and lungs when TMZ was bound with nanoparticles 
were caused by the reticuloendothelial system in these organs. 
In the brain, compared with TMZ solution, both types of 
nanoparticles, especially nanoparticles coated with 
polysorbate-80, significantly increased the accumulation of the 
drug by 2.29-fold (1.10 ± 0.19 µg/g versus 0.48 ± 0.11 µg/g).
Discussion
PBCA nanoparticles containing TMZ were prepared by 
emulsion polymerization and presented a relatively homo-
geneous shape (Figure 2), with a mean size lower than 
200 nm. These results are in agreement with recently reported 
data.28,31,32 Pluronic F68, which was used as a steric stabilizer 
for obtaining a stable nanoparticle form, would increase 
the size of the nanoparticles when its percentage was more 
than 3%.31 Additionally, the pH value would be another factor 
affecting the particle size. Both below pH 2.0 and above 
pH 3.0 would increase the particle size significantly.33,34 
Therefore, we chose Pluronic F68 1% and pH 2.5 as 
experimental conditions in the study. The zeta potential, 
which reflects particle stability, was negative (−24.8 ± 2.2 mV), 
indicating sufficient repulsion between particles to avoid 
their aggregation and formation of a stable nanoparticle 
suspension.35 The entrapment efficiency of the prepared 
nanoparticles in our study was not very high, and about 
44.23 ± 2.04% of the TMZ in the preparation was bound to 
the nanoparticles. This result might be due to the amphiphilic 
nature of TMZ, which is relatively highly lipophilic and 
somewhat soluble in water.23 Another reason may be that the 
TMZ bound to the nanoparticles mainly depended on physical 
adsorption and entrapment rather than covalent binding, as 
the results of the spectrum (Figure 3) suggest. Other 
preparation methods, like interfacial polymerization or 
miniemulsion polymerization, might be helpful to achieve a 
higher entrapment efficiency,15,16 but further studies still need 
to be done to investigate this further.
The release pattern of TMZ-PBCA nanoparticles without 
coating and coated with polysorbate-80 was noted to be 
typically biphasic, while the TMZ solution was a quick 
releasing process. The initial burst in the first hour 
indicates that some of the drug molecules could be on the 
surface of the nanoparticles and the following sustained 
release might be due to the drug entrapped in the nano-
particles. The mechanism of drug release from PBCA 
nanoparticles would be Fickian diffusion according to the 
n values (n , 0.45) calculated by the Ritger–Peppas model, 
as shown in Table 1. This result is in accordance with earlier 
findings.14,33 In   addition, it is obvious from the Figure 4 that 
coating with 1% polysorbate-80 would slightly decrease drug 
release from the nanoparticles. This might be caused by leak-
age of drug into the medium during the process of coating.28 
Furthermore, the reason for the low total cumulative release 
of the two kinds of nanoparticles might be the low amount 
of drug in the particles discussed here.
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NPs + polysorbate-80.
Table 1 The different release model of TMZ-PBcA nanoparticles 
(I) and TMZ-PBcA nanoparticles + polysorbate-80 II (n = 3)
Formulation Model
First  
order
Hixson- 
Crowell
Higuchi Ritger- Peppas
r r r r n
I 0.865 0.843 0.945 0.967 0.383
II 0.868 0.845 0.947 0.966 0.382International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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According to the in vivo results of our experiments, 
TMZ-PBCA nanoparticles coated with polysorbate-80 were 
able to promote better biodistribution of the drug into the 
brain, as compared with the free drug solution and uncoated 
drug-loaded nanoparticles. This result is in agreement with 
earlier data reported for other drugs. Lobenberg and Ambruosi 
reported that a higher brain concentration of azidothymidine 
and doxorubicin was observed one hour after administration 
of the coated nanoparticles in rats.29,30 It was also observed 
that methotrexate bound to polysorbate-80-coated nanopar-
ticles could significantly increase drug levels in the brain.36 
Other drugs that have been successfully transported across 
the blood–brain barrier and improve drug level in brain by 
using PBCA nanoparticles coated with polysorbate-80 include 
dalargin,17 loperamide,16 tubocurarine,37 MRZ 2/576, and 
gemcitabine.18,32 According to a recent study,38 polysorbate-80 
played a specific role in brain targeting, and was essential 
for the delivery of drug-loaded nanoparticles into the brain.
The exact mechanism of nanoparticle-mediated transport 
of drugs across the blood–brain barrier has yet to be determined. 
Several possibilities that could explain the mechanisms have 
been proposed. These include: an increased retention time 
of the nanoparticles in the brain capillaries which could 
enhance transport across the blood–brain barrier; the surfac-
tant effect would lead to endothelial cell membrane fluidiza-
tion and to enhanced drug permeability; the nanoparticles 
could induce opening of the tight junctions between the 
endothelial cells; the nanoparticles might be endocytosed by 
the endothelial cells to deliver the drug into the brain; the 
drug-loaded nanoparticles could be delivered into the brain 
by transcytosis; and the polysorbate-80 could inhibit the 
P-glycoprotein efflux pump.39 Among these, the most likely 
mechanism is endocytosis, which has been supported by 
many studies in the past few years.21,22,39 Nanoparticles coated 
with polysorbate-80 could covalently couple with apolipo-
protein E, A-I, or B-100 in the blood stream and then mimic 
low-density lipoprotein particles to interact with the low-
density lipoprotein receptor, leading to their uptake by brain 
capillary endothelial cells. Finally, the drug could be deliv-
ered by passive diffusion from endothelial cells to the brain 
and generate therapeutic effects.
In our experimental results, it was also observed that 
uncoated nanoparticles would lead to a significantly higher 
concentration of TMZ in the liver, spleen, and lungs after 
intravenous injection to rats in comparison with the free drug 
solution (Table 2). The reason is that these organs are rich 
in the phagocytic cells of the reticuloendothelial system, by 
which drug carriers with an average size below 7 µm are easily 
taken up in blood stream. However, the drug nanoparticle 
concentrations were significantly lower in the heart and 
kidney than for the TMZ solution (Table 2), especially the 
nanoparticles coated with polysorbate-80. This indicates that 
TMZ-PBCA nanoparticles coated with polysorbate-80 might 
decrease cardiac and renal accumulation of TMZ and reduce 
the toxicity of TMZ to the heart and kidney. This result is in 
accordance with previously reported data.13,27
Heart
Liver
Spleen
Lungs
0
4
3
1
2
6
5
T
e
m
o
z
o
l
o
m
i
d
e
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
µ
g
/
g
)
Kidneys
Brain
TMZ solution TMZ-PBCA-NPs TMZ-PBCA-NPs + polysorbate-80
Figure 5 In vivo different tissue distribution of temozolomide concentrations (µg/g) 
after  intravenous  injection  of TMZ  solution, TMZ-PBcA-NPs  and TMZ-PBcA-   
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Table 2 equations of standard curve of the organs and body distribution (in µg drug per g tissue, µg/g) after intravenous administration 
of different temozolomide formulations in rats (n=6)
Organ Equation of standard curve Formulation
I II III
heart Y = 2.10 × 105X + 1.51 × 104 (r = 0.9974) 3.29 ± 0.23 2.19 ± 0.29 1.68 ± 0.26
Liver Y = 1.86 × 105X + 1.32 × 104 (r = 0.9963) 3.26 ± 0.35 4.41 ± 0.46b 4.84 ± 0.47b
spleen Y = 2.03 × 105X + 2.39 × 104 (r = 0.9937) 2.11 ± 0.17 3.22 ± 0.31b 3.08 ± 0.25b
Lungs Y = 2.09 × 105X + 2.01 × 104 (r = 0.9969) 1.95 ± 0.12a 2.47 ± 0.24b 2.20 ± 0.32a,b
Kidneys Y = 1.85 × 105X + 2.63 × 104 (r = 0.9922) 5.17 ± 0.47 4.09 ± 0.37b 3.71 ± 0.30b
Brain Y = 2.00 × 105X + 1.97 × 104 (r = 0.9972) 0.48 ± 0.11 0.71 ± 0.12 1.10 ± 0.19
Notes: I = TMZ solution; II = TMZ-PBcA nanoparticles; I = TMZ-PBcA nanoparticles + polysorbate-80. Level of significance according to the Tukey test P , 0.05. This level is 
reached between the different groups unless indicated by superscript letters: aNonsignificant difference between I  and III; bNonsignificant difference between II  and III.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In summary, the in vitro results presented here confirm 
the sustained release effect of TMZ-PBCA nanoparticles 
against TMZ solution. Moreover, our present study confirms 
earlier findings that only drug-loaded nanoparticles coated 
with polysorbate-80 could generate a significant improve-
ment of drug levels in the brain. Altogether, our results 
confirm our hypothesis that the brain-targeting ability of 
TMZ would be enhanced when bound to PBCA nanoparticles 
coated with polysorbate-80.
Conclusion
The present results demonstrate the feasibility of encapsulat-
ing the alkylating agent, TMZ, into PBCA nanoparticles by 
polymerization. Compared with TMZ solution, TMZ-PBCA 
nanoparticles exhibited sustained release in vitro. Furthermore, 
based on the pattern of distribution in body organs, higher 
concentrations of TMZ can be detected in the brain after bind-
ing to PBCA nanoparticles coated with polysorbate-80, which 
may be more useful for treating brain tumors. The prepared 
formulation may also reduce the toxicity of chemotherapy. 
However, to serve as a drug delivery system in the treatment of 
malignant brain tumors, further investigations are required.
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